Heart failure with preserved ejection fraction: perspectives from ESC Heart Failure
Hear what the evidence — and their patients — are telling them.
Around one million people in the UK live with heart failure, and new diagnoses are expected to double by 2040. Although HFpEF and HFrEF share similar cardiovascular risks and outcomes, HFpEF remains underserved, and dedicated HFpEF services across the UK are limited.
With 1 in 5 patients with HFpEF are rehospitalised within 30 days of discharge, the need for improved management is urgent. People with HFpEF deserve equal focus.
At ESC Heart Failure in Barcelona, we spoke with two clinicians working at the front line of this challenge — exploring the realities patients face, from symptom recognition and difficult conversations around a new diagnosis, to navigating a treatment landscape where options now exist for this historically underserved group. You can access these conversations below.
Kerendia▼ (finerenone) is indicated for the treatment of symptomatic chronic heart failure with LVEF ≥40% in adults.
Please double click on the video to view it full screen.
Living with Heart Failure: How Specialist Nurses Champion Patient Wellbeing, Insights from the ESC-HF Congress
Delyth Rucerean | Heart Failure Nurse Specialist, Morriston Hospital, Swansea Bay University Health Board, Chair of the BSH Nurse Forum
From ESC-HF to Practice: Evidence-Based Strategies for Heart Failure Management
Professor Patricia Campbell | Heart Failure Cardiologist, Southern Trust, Northern Ireland, Heart Failure Lead for Northern Ireland and a member of the BSH Board.
PP-KER-GB-1032 | July 2026